|
|
Article: ALTUS GETS POSITIVE RESULTS FROM ONCE-PER-WEEK GROWTH HORMONE.
- Article from:
- Biotech Business
- Article date:
- August 1, 2006
CopyrightCOPYRIGHT 2006 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Altus Pharmaceuticals Inc. (Nasdaq: ALTU), Cambridge, Mass. a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic diseases, has announced results from a multi-center Phase II clinical trial in growth hormone deficient adults for ALTU-238, a long- acting crystalline formulation of recombinant human growth hormone (hGH, somatropin). ALTU-238 is being developed as a subcutaneously administered, once-per-week formulation of human growth hormone that employs Altus' proprietary protein crystallization and formulation technology.
The Phase II clinical ...